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Background. Prescription of fragmented tablets is useful for individualisation of dose but includes several drawbacks. Although
without score lines, the antipsychotic drug quetiapine was in 2011 the most often prescribed 1/2 tablet in discharge prescriptions at
the University Hospital in Basel (USB, 671 beds). We aimed at analysing the prescription patterns of split tablets in general and of
quetiapine in particular in Switzerland.Methods. All orders of community pharmacies for unit-of-use soft pouch blisters placed at
MedifilmAG, the leader company in Switzerland for repackaging into pouch blisters, were analysed.Results. Out of 4,784,999 tablets
that were repacked in 2012 in unit-of-use pouch blisters, 8.5% were fragmented, mostly in half (87.6%), and were predominantly
psycholeptics (pipamperone 15.8%). Prescription of half quetiapine appears to be a Basel specificity (highest rates of fragments
and half quetiapine). Conclusions. Prescription of fragmented tablet is frequent. It represents a safety issue for the patient, and a
pharmaceutical care issue for the pharmacist. In ambulatory care, the patient’s cognitive and physical capacities must be clarified,
suitability of the splitting of the tablet must be checked, appropriate aids must be offered, like a pill-splitting device in order to
improve accuracy, and safe use of the drug must be ensured.
1. Introduction
Previous studies showed that fragmenting concerns every
fourth tablet in ambulatory setting [1, 2] predominantly
because of dose adjustment, swallowing difficulties, or costs
[3–5]. However, some drawbacks exist such as breaking
difficulties, breaking in unequal parts, and loss of mass [5].
Further, changing the dosage form may degrade the active
substance at the fractured surface and thus alter its absorption
characteristics. The site of action may not be reached, which
may be clinically relevant, especially for substances with
narrow therapeutic index [6]. The keeping of the halves may
be difficult because of problems of stability and of identifi-
cation. Further, controlled release forms are unsuitable for
splitting, since their destruction can lead to dose-dumping
and dose-dependent side effects by altering the liberation
kinetics of the substance. Finally, substances with irritating or
toxic properties, especially the CMR substances (carcinogen,
mutagen, or toxic for reproduction), should be split only with
protective measures (e.g., gloves and masks) [7].
The European regulatory authorities evaluated splitting
tablets into segments [8]. This apparently simple operation
bears a potential for dosage error that increases if the tablets
are not scored. In view of the many exceptions where
splitting is not allowed (enteric coated tablets, layered tablets,
and many modified release dosage forms), the authorities
concluded thatmanufacturers should provide information on
the issues surrounding cutting tablets into smaller segments.
In USA, the FDA, the American Medical Association, and
other medical organizations consider tablet splitting as a
risky practice and advise against it unless it is specified in
the drug’s labeling [9]. The analysis of electronic medication
regimens from 54 wards of a large university hospital in
Germany showed that 12.5% of all drugs were prescribed
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in split form [10]. Splitting was inappropriate for 2.7% of
all drugs, mainly because of the absence of a score line.
A retrospective study performed at the University Hospital
Basel in Switzerland showed similar results [11]. Of the 36,751
electronic prescriptions delivered in 2011 at discharge, 3,724
(10.1%) contained the mention “1/2” and concerned 4,888
single tablets. Of those 1/2 tablets, 16.4% were wrongly
prescribed, predominantly due to inexistent score lines.
Quetiapine (Seroquel, Sequase 25mg), a tablet with no score
line, was the drug most often wrongly prescribed as half
tablet.
Quetiapine is an atypical or second-generation antipsy-
chotic agent similar in structure to clozapine and exhibits
strong antagonism of 5HT
2
receptors and weak antagonism
of D
2
receptors [12]. It is approved for the treatment of
schizophrenia and bipolar disorders [13] and is widely used
mainly because it does not induce agranulocytosis [14] and
thus does not require blood monitoring. Its substantial
advantage is further a favourable profile of acute extrapyra-
midal side effects that occur in very rare cases [15]. Off-
label use, that is, unlabeled or unapproved use, is common
in conditions such as agitation, anxiety, dementia, obsessive-
compulsive disorders, psychosis [16], and delirium [17, 18].
Because of many inconclusive study results, evidence is
limited. A meta-analysis of seven randomized controlled
studies with 3,257 participants evaluated the effects of que-
tiapine for anxiety disorders at doses ranging between 25
and 400mg/day [19]. Monotherapy with quetiapine was
better than placebo in reducing symptoms of generalized
anxiety disorder and was equivalent to antidepressants in
improving depressive symptoms. In all studies, more subjects
in the quetiapine group left the trials early due to adverse
events (gained weight and sedation). The additional use of
quetiapine at doses between 25 and 600mg/d was established
in a furthermeta-analysis only in the treatment of generalized
anxiety disorder [16].The small clinical studiesmostly started
doses at 25mg/day [20–22]. We were able to find low-
dose quetiapine at 12.5mg only in one Italian study for the
initiation of treatment in 41 patients with dementia and
concomitant psychotic disorders [23] and in one Spanish
study with 7 Parkinson’s patients, where low-dose quetiapine
was effective on psychotic symptoms, sleep disturbances, and
stress of the caregivers [24].
Building up on the local observation of 2012, we aimed
at analysing the general prescription patterns of split tablets
in Switzerland. Thus, the questions of interest are as follows.
“What is the prevalence of split tablets in Switzerland? Is the
wrong prescription of half quetiapine tablets restricted to a
local habit in Basel?” Further, we aimed at evaluating the
consequences of split tablets for community pharmacies,
patients, and patient care organisations and discussing some
recommendations for daily practice.
2. Material and Methods
We obtained all orders placed by Swiss community pharma-
cies at Medifilm AG, the leader company in Switzerland in
the repackaging of medication into unit-of-use soft pouch
blisters, located in the industrial area of Oensingen (canton
Solothurn) [25]. Community pharmacists can order rolls of
single pouches containing various medications to be taken
at one time, mainly for long-term institutionalized patients.
Segments of tablets can be ordered without restriction.
Orders are submitted to quality assurance checks. When split
tablets are required and corresponding lower dosage strength
is available as single tablet on the market, an exchange
takes place. If no lower dosage strength is available and the
formulation of the tablet is conventional (i.e., no enteric
coat and no modified release), the tablet is fragmented with
an automatic pill-splitter. According to the Summary of
Product Characteristics [13], quetiapine tablet is a round,
6mm in diameter, film-coated tablet without score line. Since
its formulation is without functional coating, the splitting
of the lowest strength of quetiapine tablet (Seroquel 25mg
original brand and Sequase 25mg generic brand approved
since 09/2011) is performed.
Presence of a score line and suitability for splitting of
tablets were obtained from the Swiss Summary of Products
Characteristics [13]. Archive files were retrieved from the
open drug database http://ch.oddb.org/.
3. Statistics
We used the SPSS statistical package version 21.0 (SPSS Inc.,
Chicago, IL, USA) for data description and the R system
for computation and graphics (v3.1.3, R Core Team (2015);
R: a language and environment for statistical computing;
R Foundation for Statistical Computing, Vienna, Austria,
http://www.R-project.org/). Additional graphics were created
with Power Map Preview for Excel 2013 (Microsoft Excel
[computer software], Microsoft, 2013, Redmond, Washing-
ton, USA).
4. Results
Between January 1 andDecember 31, 2012, a total of 4,784,999
tablets were packed in unit-of-use soft pouch blisters by
Medifilm. Of these, a total of 406,956 (8.5%) were fragments
of tablets that had been ordered by 29 community pharmacies
for 1,321 patients residing in 53 retirement homes inNorthern
Switzerland. The homes have used in 2012 between 14 and
48,300 fragmented tablets (Table 1). The patients were in
average 81.5 ± 14.7 years old (median: 86; range: 7–105) and
obtained in average 1.7 fragments (median: 1; range: 1–8). A
total of 577 (43.7%) patients received two or more fragments
of tablets (Table 2).Themajority of the fragments were halves
(356,339; 87.6%) and quarters (45,375; 11.1%) and marginally
thirds, two-thirds, and three-quarters (5,242; 1.3%; Figure 1).
The fragments concerned 132 different active substances,
and 50% of them were psycholeptics or psychoanaleptics
(Figure 1). The most often split tablets were preparations
with pipamperone (15.8%), levodopa/decarboxylase inhibitor
(10.2%), and quetiapine (6.5%; Table 3). The ten most often
fragmented tablets accounted for 57% of all split tablets
(Table 3).
The highest proportion of fragmented tablets was
ordered for homes located in Northern Switzerland, that
is, Basel (89,980; 22.1%), Bern (61,707; 15.2%), and Baden
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Table 1: Fragments and half quetiapine tablets by home (𝑁 = 53) as frequency and as proportion of the total number of fragments (𝑁 =
406,956). The cantons are given by their official abbreviations: BE, Bern: BS, Basel-Stadt; AG, Aargau; SO, Solothurn; BL, Basel-Landschaft;
LU, Lucerne; ZH, Zurich; SG, St. Gallen; GR, Grisons.
Home ID Number of fragments (%) Number of half quetiapine tablets (%) Cantons
BE BS AG SO BL LU ZH SG GR
1 48300 (11.9) 409 (0.1) x
2 28255 (6.9) 1142 (0.3) x
3 22835 (5.6) 2445 (0.6) x
4 22415 (5.5) 578 (0.1) x
5 21996 (5.4) 988 (0.2) x
6 21178 (5.2) 3699 (0.9) x
7 20853 (5.1) 2478 (0.6) x
8 20840 (5.1) 458 (0.1) x
9 19557 (4.8) 3862 (0.9) x
10 18992 (4.7) 1597 (0.4) x
11 16065 (3.9) 778 (0.2) x
12 15756 (3.9) 1774 (0.4) x
13 14568 (3.6) x
14 14517 (3.6) 862 (0.2) x
15 13368 (3.3) 21 (0.01) x
16 11539 (2.8) 854 (0.2) x
17 10083 (2.5) 2133 (0.5) x
18 9861 (2.4) 582 (0.1) x
19 5963 (1.5) x
20 5868 (1.4) x
21 4990 (1.2) x
22 4968 (1.2) x
23 4466 (1.1) x
24 3518 (0.9) 775 (0.2) x
25 3124 (0.8) x
26 2526 (0.6) 523 (0.1) x
27 2480 (0.6) x
28 2435 (0.6) x
29 2334 (0.6) x
30 1456 (0.4) x
31 1427 (0.4) x
32 1078 (0.3) x
33 1004 (0.2) x
34 980 (0.2) 28 (0.01) x
35 905 (0.2) x
36 890 (0.2) x
37 836 (0.2) 126 (0.03) x
38 771 (0.2) x
39 751 (0.2) 223 (0.1) x
40 719 (0.2) x
41 514 (0.1) x
42 414 (0.1) x
43 291 (0.1) x
44 276 (0.1) x
45 267 (0.1) x
46 224 (0.1) x
47 159 (<0.1) x
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Table 1: Continued.
Home ID Number of fragments (%) Number of half quetiapine tablets (%) Cantons
BE BS AG SO BL LU ZH SG GR
48 133 (<0.1) x
49 125 (<0.1) x
50 39 (<0.1) x
51 19 (<0.1) x
52 14 (<0.1) x
53 14 (<0.1) x
Total 406,956 (100%) 26,356 (6.5%) 8 9 8 11 5 5 3 1 1
Table 2: Number of split medications by patient (𝑁 = 1,321
patients).
Number of
fragments
Number of
patients (%)
Cumulative number
of patients (%)
1 744 (56.3) 744 (56.3)
2 350 (26.5) 1,094 (82.8)
3 139 (10.5) 1,233 (93.3)
4 65 (4.9) 1,298 (98.2)
5 15 (1.1) 1,313 (99.3)
6 5 (0.4) 1,318 (99.7)
7 2 (0.2) 1,320 (99.9)
8 1 (0.1) 1,321 (100)
(38,503; 9.5%; Figure 2, heat map). The most split quetiapine
tablets were ordered in Basel (10,273; 39%; Figure 2, bars)
compared to the rest of Switzerland (i.e., French and Italian
speaking parts).
5. Discussion
Fragments of tablets represented 8.5% of all tablets ordered in
2012 by 53 community pharmacies in Northern Switzerland
for institutionalized patients. This value is probably below
the effective prescription rates of fragmented tablets since
splitting at the companyMedifilm is reserved for cases where
no lower dosage strength is available on the market. Conse-
quently, the actual value of dispensed fragmented tablets in
ambulatory setting might be higher, given that the exchange
for a commercially available lower strength is not automated
in community pharmacists during routine practice. A recent
study in Swedish community pharmacies showed that 52.5%
of the patients with a prescription for split tablets preferred
whole tablets of the appropriate strength rather than split
tablets [26]. Nevertheless, prescribing fragments of tablets
appears to be a very common practice in the ambulatory
setting.
Out of the 10 most often ordered split tablets, two
(quetiapine and risperidone) had doubtful legitimacy to be
fragmented since the decision cannot be backed up with the
product information. Although splitting a tablet that is not
intended to be fragmented does not seem to be a prescribing
error [27–29], it may reduce drug effectiveness and induce
toxicity and thus represents a safety issue.
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Figure 1: Distribution of the ten most often split tablets sorted by
ATC therapeutic main group (𝑁 = 406,956).
Wrong prescription of 1/2 tablets usually does not cause
significant patient harm, since, for many drugs, especially
those with a wide therapeutic range and a long half-life,
dose fluctuations are unlikely to be clinically significant. The
above applies for quetiapine even more since its formulation
is without functional coating or modified release.
In any case, some pitfalls exist when fragmenting tablets
that are not intended to. First, patientsmay be easily confused
about the correct dose. An effective instruction of the patients
by the health professional is a prerequisite to minimise intake
errors, especially when patients received information at the
time of hospital discharge that diverges from the finally
dispensed medication, for example, obtaining half tablets
during hospitalization, leading to an initial prescription of
a half tablet that is modified to one tablet of a lower dose.
In the worst case, patients may split the wrong medication
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Table 3: Ten most frequently split medications given by active substances (SPC: Summary of Product Characteristics).
Active substance
(original brand name)
Proportion of split tablets [%] Splitting is explicitly
mentioned in the SPC
(yes/no)
Total
(cumulative)
Quarter
1/4
Half
1/2
Three-quarter
3/4
Pipamperone (Dipiperon) 15.8 6.2 9.3 0.3 y
Levodopa/decarboxylase
inhibitor (Madopar) 10.2 (26.0) — 10.1 0.1 y
Quetiapine (Seroquel,
Sequase) 6.5 (32.5) 0.3 6.2 — n
Lorazepam (Temesta) 5.1 (37.6) 0.4 4.7 — y
Mirtazapine (Remeron,
generics) 4.3 (41.9) — 4.3 — y
Torasemide (Torem,
generics) 3.9 (45.8) 2.2 1.2 0.5 y
Zolpidem (Stilnox,
generics) 3.2 (49.0) — 3.2 — y
Metoprolol (Beloc ZOK,
generics) 2.7 (51.7) — 2.7 — y
Citalopram (Seropram,
generics) 2.7 (54.4) — 2.7 — y
Risperidone (Risperdal) 2.6 (57.0) — 2.6 — n
Bern (BE)
Basel 
(BS)
Baden 
(AG)
Oensingen (SO)
Zurich (ZH)
Proportion of split quetiapine preparations
(higher columns represent higher proportion)
Biel (BE)
Lucern (LU)
Laufen (BL)
Total proportion of split preparations (%)
0.0 12.0
Figure 2: Geographical distribution of split tablets in general (heat map; the warmer the colour (i.e., red), the higher the frequency,
independently of the surface) and of half quetiapine tablets (purple bars; the higher the column, the higher the proportion) for each of
the 51 retirement homes (𝑁 = 406,956). Grey areas indicate cantonal borders. The two distant homes located in cantons SG and GR (<0.1%
split tablets; no quetiapine) are not depicted.
and take too few or too much medication. Second, patients
might have poor visual acuity or dexterity that renders
fragmenting very uncertain.They need at least the right tools
and should be given a pill-splitting device to improve accu-
racy. Third, patients may store the remaining fragments or
crumbles inadequately, whichmay affectmedication stability,
or use a container with no labelling, which renders a later
identification of the fragments almost impossible. Fourth,
patients may split several medications, which seems to be
a frequent situation with 43.7% of our patients obtaining
two fragments or more. Because the identification of the
fragments is limited, the presence of multiple fragments
represents probably the most risky situation, with a wrong
intake resulting invariably from one handling error.
Given the potential risks, it is striking that half of
the splitting concerned psychoactive substances in this
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elderly population. However, the appropriateness of splitting
tablets may result from clinical observation. Because most
manufacturer-based researches exclude frail elderly, and as
such the appropriate dose for such patients, the prescription
of split tabletsmay be the result of oversedation observedwith
whole tablets.
All above mentioned processes may represent safety
issues, be time-consuming for patients, their relatives, or
carers in charge of the medication managements, and ulti-
mately generate costs that may clear the savings initially
advocated for splitting tablets [30]. Finally, since handwritten
prescriptions are still common,misreading by the pharmacist
of one-half (1/2) as one to two (1-2) tablets can only be
ruled out if prescribers would order strength and dose of the
medication in milligrams [31].
The USB is a 671-bed teaching hospital in Northwestern
Switzerland and serves as a major referral centre for the 1-
million region. At the USB, quetiapine is administered off-
label for the prevention of delirium in the postoperative
setting, starting at doses of 5mg/day with 5mg capsules
exclusively produced at the hospital pharmacy. Quetiapine
is also used off-label for the therapy of delirium according
to an internal scheme [32], where multiple doses of 12.5mg
up to 50mg/24 h (<80 years) or 5mg up to 25mg/24 h (>80
years) are administered on the first day, with doubling of the
dose on the second day. According to this scheme, therapy
should be reduced or stopped after 5 days. On the wards at
the USB, a dose of 12.5mg quetiapine is administered as 1/2
tablet of 25mg strength according to a recommendation note
of the division of acute geriatrics. Quetiapine is the favourite
drug for hospitalised elderly who are slightly disorientated
andmildly agitated, for example, who standup and are at risks
of falling. Further, quetiapine has a short half-life, an antihis-
taminic action, and a lower incidence of QTc prolongation
compared with haloperidol, the standard delirium therapy.
From a clinical point of view, trials on pharmacological
prevention of delirium did not show conclusive results
[33]. No controlled maintenance treatment trials have been
conducted with quetiapine, unlike all other atypical antipsy-
chotics which have demonstrated a positive effect on relapse
prevention [15]. In studies that investigated effects onnegative
symptoms (emotional and social withdrawal, poverty of
speech, lack of drive and motivation, and disinterest) and
used haloperidol as the comparator drug, quetiapine did not
show any advantage [15]. Independently of the (non)existing
evidence, the internal scheme used at the USB recommends
reducing or stopping treatment with quetiapine after 5 days;
this information seems to get lost during hospitalisation.
Neglecting annotating the duration of use, that is, the “stop”
date of a treatment, represents a prescription error whichmay
be costly [34]. Further, preventive pharmacological therapy
in geriatric patients can expose them to the unnecessary risk
of adverse effects. Furthermore, all antipsychotics including
quetiapine are listed in the Beers Criteria as potentially
inappropriate for use in elderly patients (quetiapine is an
exception for patients with Parkinson’s disease) [35]. Thus,
continued antipsychotic therapy in geriatric patients should
be reevaluated at each care transition and stopped in absence
of clear indication. Particularly noteworthy is the fact that
low-dose quetiapine does not seem to be administered for
its antipsychotic effects but rather for its sedative effects in
the elderly hospitalised patients in an empiric manner and in
absence of clear evidence for a proven alternative.
Finally, it seems that the irrational case of 1/2 quetiapine
25mg remains confined to Basel and its clinics and did not
spread out. However, the level is surprisingly high when
one considers that 5 years had passed since the official
introduction of the recommendation in the division of acute
geriatrics.
The observation that community pharmacies ordering
unit-of-use soft pouch blisters were massively located in
Northern Switzerland (with one marginal exception in
Grisons) may reflect a cultural difference between German
speaking regions in the North and French and Italian speak-
ing regions in the South and is not a limitation.
6. Conclusions
Tablet splitting has a major role in dosage adjustment and
should be limited to specific clinical situation, that is, titration
of dose and pediatric and geriatric patients, and according to
the recommendation of the productmanufacturer. Physicians
who prescribe a split tablet that is not intended to be frag-
mented and pharmacists who dispense the drug accordingly
should be aware that this renders the medication unlicensed.
Since resolving the uncertainty about the prescription by
the pharmacists or the nurses results in much unnecessary
work, splitting tablet is not suited as a method of general
cost reduction. Taking into account all problems linked
to the handling of a half tablet (patients’ dexterity and
eyesight, conservation and confusion of the halves, wastage,
and therapeutic compliance), prescribing 1/2 tablet represents
a safety issue. Thus, prescribers should make effort to use
commercially available whole tablets. If splitting tablets is still
necessary, patient counseling is recommended and pharma-
cies should deliver the appropriate tools or pharmacists split
the tablets for the patient and repackage them.
Quetiapine 25mg remains the third most often pre-
scribed half tablet in Northern Switzerland in general and the
first specifically in Basel. As off-label prescribing is claimed to
be not evidence-based, to undermine the regulatory system,
to be costly, to put the patient at risk, and to impact negatively
on pharmaceutical innovation [36], this situation is more
than frightening. It is usually in the company’s interests
to extend the indications of its products. However, in this
particular case, the pharmaceutical industry seems to limit
its investment probably because generic formulations are
available. Pharmaceutical companies should be encouraged
to introduce new strengths to an existing range of products, in
view of an optimisation of seamless care between the different
health care professionals.
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